Phosphodiesterase inhibition by new cardiotonic agents: Mechanism of action and possible clinical relevance in the therapy of congestive heart failure
- 1 June 1989
- journal article
- review article
- Published by Springer Nature in Klinische Wochenschrift
- Vol. 67 (12), 605-615
- https://doi.org/10.1007/bf01718141
Abstract
Cyclic AMP is known as a secondary messenger regulating the myocardial force of contraction. For the degradation of cAMP multiple forms of PDE within the cell are described, which vary according to substrate specificity, kinetic characterization, and cellular localization. One of these isoenzymes, the low Km cAMP-specific PDE (PDE III), which seems to be closely related to cardiotonic effects of PDE inhibitors, exists either in a particulate form (in dogs), probably associated with the sarcoplasmic reticulum, or in a soluble form (in guinea pig). The existence of different forms of PDE III possibly reflects a different pooling or compartmentalization of cAMP. Many agents selectively inhibiting PDE III are described which potently increase the force of contraction and which exert vasodilatory effects. Besides PDE inhibition some of these agents possess additional cAMP-independent actions, e.g., sensitization of the contractile proteins to Ca2+, prolongation of the action potential, or prolongation of the open state of the Na+-channel. Since agents which nonselectively inhibit PDE are known as potent positive inotropic agents (e.g., IBMX), PDE III inhibition itself, but not a selectivity for PDE III inhibition, seems to be a prerequisite for this mechanisms of action of cardiotonic drugs. Investigations with preparations from diseased human myocardium show that the β-adrenoceptor agonist isoprenaline as well as the PDE inhibitor IBMX increase the force of contraction to only about one-third of the maximal effect of the cardiac glycoside dihydro-ouabain or Ca2+. In nonfailing human heart preparations all agents had equal activity. Possible reasons for these differences may be a decreased responsiveness to β-adrenoceptor stimulation (β-receptor down-regulation) or an inappropriate increase in cAMP levels due to increased activity of inhibitory Gi-proteins with resulting decrease of adenylate cyclase activity in the failing heart. Besides a short-term clinical and hemodynamic improvement of congestive heart failure, uncontrolled long-term administration of PDE III-inhibitor agents failed to produce sustained clinical benefit and had no effect on survival. Controlled long-term studies with new cardiotonic agents in patients with severe CHF are still lacking.Keywords
This publication has 117 references indexed in Scilit:
- Inotropic response in CHF: Myocarditis vs dilated cardiomyopathyAmerican Heart Journal, 1988
- Central and regional hemodynamic effects of oral enoximone in congestive heart failure: A double-blind, placebo-controlled studyAmerican Heart Journal, 1988
- The effectiveness of inotropic agents in isolated cardiac preparations from the human heartKlinische Wochenschrift, 1988
- Piroximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failureAmerican Heart Journal, 1987
- New Positive Inotropic Agents in the Treatment of Congestive Heart FailureNew England Journal of Medicine, 1986
- Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement.Circulation, 1985
- Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.Circulation, 1984
- Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human HeartsNew England Journal of Medicine, 1982
- Hemodynamic Assessment of AmrinoneNew England Journal of Medicine, 1978
- New cardiotonic agents: A search for digitalis substituteLife Sciences, 1978